Q3 EPS Estimates for Tango Therapeutics Lifted by Wedbush

Key Points

• Analysts at Wedbush have raised their Q3 2025 earnings per share estimate for Tango Therapeutics from (0.37) to (0.35), while the full-year consensus estimate remains at (1.19) EPS.
• Guggenheim increased its price target for Tango Therapeutics from $8.00 to $10.00 and maintains a "buy" rating, with an average consensus price target set at $11.00.
• Tango Therapeutics reported a Q2 revenue of $3.18 million, significantly below the analyst estimates of $6.41 million, alongside a negative net margin of 599.11%.

Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Equities research analysts at Wedbush increased their Q3 2025 EPS estimates for Tango Therapeutics in a research report issued on Tuesday, August 5th. Wedbush analyst R. Driscoll now expects that the company will earn ($0.35) per share for the quarter, up from their prior estimate of ($0.37). The consensus estimate for Tango Therapeutics' current full-year earnings is ($1.19) per share. Wedbush also issued estimates for Tango Therapeutics' Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($1.38) EPS, Q1 2026 earnings at ($0.32) EPS, Q2 2026 earnings at ($0.33) EPS, Q3 2026 earnings at ($0.34) EPS, Q4 2026 earnings at ($0.35) EPS and FY2026 earnings at ($1.33) EPS.

TNGX has been the subject of a number of other research reports. Guggenheim raised their target price on shares of Tango Therapeutics from $8.00 to $10.00 and gave the stock a "buy" rating in a research note on Wednesday, August 6th. HC Wainwright restated a "buy" rating and issued a $13.00 price target on shares of Tango Therapeutics in a research report on Monday, April 14th.

Tango Therapeutics Price Performance

TNGX stock traded down $0.33 during trading hours on Thursday, reaching $6.29. The stock had a trading volume of 526,185 shares, compared to its average volume of 1,770,838. The stock has a market capitalization of $699.27 million, a PE ratio of -4.72 and a beta of 1.64. The stock has a 50-day simple moving average of $5.56 and a 200 day simple moving average of $3.18. Tango Therapeutics has a fifty-two week low of $1.03 and a fifty-two week high of $12.02.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($0.35) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.35). The company had revenue of $3.18 million during the quarter, compared to the consensus estimate of $6.41 million. Tango Therapeutics had a negative net margin of 599.11% and a negative return on equity of 79.72%.

Institutional Trading of Tango Therapeutics

Institutional investors have recently made changes to their positions in the company. CWM LLC boosted its position in Tango Therapeutics by 182.2% during the second quarter. CWM LLC now owns 4,905 shares of the company's stock worth $25,000 after purchasing an additional 3,167 shares during the period. Dynamic Technology Lab Private Ltd bought a new position in Tango Therapeutics during the fourth quarter valued at approximately $33,000. Stonebrook Private Inc. bought a new position in shares of Tango Therapeutics in the fourth quarter worth approximately $34,000. Ameriprise Financial Inc. bought a new position in shares of Tango Therapeutics in the fourth quarter worth approximately $35,000. Finally, Sherbrooke Park Advisers LLC bought a new stake in Tango Therapeutics in the fourth quarter valued at $38,000. Institutional investors own 78.99% of the company's stock.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.